Multiple pathway-level targets

Multiple pathway-level targets is a non-specific classification used in pharmacology to describe therapeutic agents that exert their effects by interacting with several distinct biological pathways simultaneously rather than a single molecular entity (Source: PubMed, PMC3730703). This concept is central to polypharmacology, where a single drug is designed to modulate complex biological networks to treat multifactorial diseases like cancer and metabolic syndrome (Source: Nature Reviews Drug Discovery). For example, multi-kinase inhibitors like sorafenib target various signaling cascades, including the RAF/MEK/ERK pathway and VEGFR, to inhibit both tumor cell proliferation and angiogenesis (Source: FDA, NCI). Similarly, drugs like metformin exhibit a systemic effect by influencing multiple cellular processes, including AMPK activation and mitochondrial complex I inhibition (Source: StatPearls). While targeting multiple pathways can overcome biological redundancy and drug resistance, it significantly increases the complexity of characterizing the drug's safety profile. The primary challenges associated with this target class include a higher potential for off-target toxicities and the difficulty of establishing precise biomarkers for patient selection (Source: NCBI, Bookshelf).

Other names

Multi-targetPolypharmacological targetsNetwork-level targetsPathway-based targetsSystemic targets

Simultaneous modulation of multiple signaling pathways and molecular nodes to achieve a therapeutic effect.